Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Cardiac injury, as measured by troponin elevation, has been reported among hospitalized coronavirus disease 2019 (COVID-19) patients and portends a poor prognosis. However, how the dynamics of troponin elevation interplay with inflammation and coagulation biomarkers over time is unknown. We assessed longitudinal follow-up of cardiac injury, inflammation and coagulation markers in relation to disease severity and outcome.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We retrospectively assessed 2068 patients with laboratory-confirmed COVID-19 between January 29 and April 1, 2020 at Tongji Hospital in Wuhan, China. We defined cardiac injury as an increase in high sensitivity cardiac troponin-I (hs-cTnI) above the 99th of the upper reference limit. We explored the dynamics of elevation in hs-cTnI and the relationship with inflammation (interleukin [IL]-6, IL-8, IL-10, IL-2 receptor, tumor necrosis factor-α, C-reactive protein) and coagulation (d-dimer, fibrinogen, international normalized ratio) markers in non-critically ill versus critically ill patients longitudinally and further correlated these markers to survivors and non-survivors.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Median age was 63 years (first to third quartile 51–70 years), 51.4% of whom were women. When compared to non-critically ill patients (<em>N</em> = 1592, 77.0%), critically ill (defined as requiring mechanical ventilation, in shock or multiorgan failure) patients (<em>N</em> = 476, 23.0%), had more frequent cardiac injury on admission (30.3% vs. 2.3%, <em>p</em> < 0.001), with increased mortality during hospitalization (38.4% vs. 0%, p < 0.001). Among critically ill patients, non-survivors (<em>N</em> = 183) had a continuous increase in hs-cTnI levels during hospitalization, while survivors (<em>N</em> = 293) showed a decrease in hs-cTnI level between day 4 and 7 after admission. Specifically, cardiac injury is an independent marker of mortality among critically ill patients at admission, day 4–7 and 8–14. Consistent positive correlations between hs-cTnI and interleukin (IL)-6 on admission (<em>r</em> = 0.59), day 4–7 (<em>r</em> = 0.66) and day 8–14 (<em>r</em> = 0.61; all <em>p</em> < 0.001) and d-dimer (at the same timepoints <em>r</em> = 0.54; 0.65; 0.61, all p < 0.001) were observed. A similar behavior was observed between hs-cTnI and most of other biomarkers of inflammation and coagulation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Cardiac injury commonly occurs in critically ill COVID-19 patients, with increased levels of hs-cTnI beyond day 3 since admission portending a poor prognosis. A consistent positive correlation of hs-cTnI with IL-6 and d-dimer at several timepoints along hospitalization could suggest nonspecific cytokine-mediated cardiotoxicity.</p>

ASSOCIATION BETWEEN ELEVATED HIGH SENSITIVITY CARDIAC-TROPONIN I LEVELS AND INCREASE IN LEVELS OF C-REACTIVE PROTEIN, INTERLEUKIN-6, D-DIMER, AND CONSEQUENT CARDIAC INJURY AND MORTALITY FOR PATIENTS WITH CORONAVIRUS DISEASE 2019: A META-ANALYSIS

Cardiac Troponin I Association with Critical Illness and Death Risk in 726 Seriously Ill COVID-19 Patients: A Retrospective Cohort Study.

Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis

Elevated High Sensitivity Cardiac Troponin T is Nonlinearly Associated with Poor Prognosis in Aging COVID-19 Patients: A Retrospective Study.

Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease

Elevated Cardiac Troponin I as a Mortality Predictor in Hospitalised COVID-19 Patients

The Peak Levels of Highly Sensitive Troponin I Predicts In-Hospital Mortality in COVID-19 Patients with Cardiac Injury: a Retrospective Study.

Cardiac Troponin I Associated with Poor Prognosis and Death Risk in 726 Severe and Critical COVID-19 Patients: A Retrospective Cohort Study

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

Analysis of Influencing Factors Related to Elevated Serum Troponin I Level for COVID-19 Patients in Yichang, China.

Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19

High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19

Factors associated with acute cardiac injury and their effects on mortality in patients with COVID-19

Serum Levels of Homocysteine, Troponin-I, and High Sensitive C-Reactive Protein in Iraqi COVID-19 patients

Risk Factors for Mortality of Coronavirus Disease 2019 (COVID-19) Patients During the Early Outbreak of COVID-19: a Systematic Review and Meta-Analysis

Joint Predictive Value of Ctni and NT-proBNP on Mortality in Patients with Coronavirus Disease 2019: A Retrospective Research in Wuhan, China

Association of inflammatory biomarker abnormalities with mortality in COVID-19: a meta-analysis

Characteristics and Clinical Significance of Myocardial Injury in Patients with Severe Coronavirus Disease 2019

Association of COVID-19 Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Cycle Threshold Value With Surrogate Markers of Disease Severity

Serial high sensitivity troponin sampling in patients with SARS-CoV-2 infection

Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression